The ECHO-7 virus is non-pathogenic and the virus is also not genetically engineered. In Latvia, the ECHO-7 virus from RIGVIR® is used since 2011 and approved for the treatment of malignant melanoma. Also in Latvia, a Virotherapy using RIGVIR® is paid for by the national health insurance. The Latvian Virotherapy Center in Riga / Latvia is researching the use of its RIGVIR® viruses for over 40 years.
RIGVIR® is injected intramuscularly and if possible near a lymph node.
As with most cancer therapies, it is utmost important to begin a therapy as soon as possible in order to minimize the risk of metastases. It is not uncommon, that an oncolytic Virotherapy begins way in advance of a surgery.
If no metastases are present, RIGVIR® is usually administered every 4 weeks for the first quarter. With metastases present, weekly injections or 3 injection in three days every 4 weeks for the first quarter are recommended and provided for by the Hyperthermia Centre Hannover.
Studies from Latvian Virotherapy Center in Riga/Latvia to RIGVIR® Virotherapy show that long term therapy plans represent the least risk of a relapse. The time intervals between injections might then be up to three (3) months. Of cause, thorough medical examinations including blood tests are provided for.
A Virotherapy has only mild side effects. The most common side effect is a slightly elevated body temperature, or a slight chill. Both can hold on for 1-3 days.
The effectiveness of oncolytic virotherapy has been studied and proved in many clinical studies. In Melanoma Research from Oct. 2015 Vol . 25 , 421-426 a retrospective investigation was published.
The study proves that the patients with melanoma in stage IIB – IIC have a 4-6 times longer life expectancy after a treatment with RIGVIR®, when compared to patients who received conventional melanoma therapy.
Main indications of oncolytic virotherapy with RIGVIR® are:
- Stomach cancer
- Colon cancer
- Pancreas cancer
- Kidneys cancer
- Uterus cancer
- Bladder cancer
- Lung cancer
- Prostate cancer
- All types of sarcoma